Patisiran (Onpattro®)

Patisiran (Onpattro®) has been available for reimbursement under hospital pricing approval since 1st October 2021. A Managed Access Protocol (MAP) is in place for patisiran. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of patisiran under hospital pricing approval.

The prescribing of patisiran under hospital pricing approval is confined to consultants with experience in the diagnosis and management of hereditary transthyretin-mediated (hATTR) amyloidosis in specialist centre(s) in Ireland, who have agreed to the terms of the MAP and have been approved by the HSE.​

The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

A copy of the HSE-Managed Access Protocol for patisiran and the application form for individual reimbursement approval can be found in the Related Files section below.

For further information, please contact